As of May 27
| +0.63 / +0.54%|
The 12 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 139.50, with a high estimate of 229.00 and a low estimate of 97.00. The median estimate represents a +18.44% increase from the last price of 117.78.
The current consensus among 13 polled investment analysts is to Buy stock in United Therapeutics Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.